Dragovich P S, Zhou R, Skalitzky D J, Fuhrman S A, Patick A K, Ford C E, Meador J W, Worland S T
Agouron Pharmaceuticals, Inc., San Diego, CA 92121, USA.
Bioorg Med Chem. 1999 Apr;7(4):589-98. doi: 10.1016/s0968-0896(99)00005-x.
The optimization of a series of irreversible human rhinovirus (HRV) 3C protease (3CP) inhibitors is described. These inhibitors are comprised of an L-Leu-L-Phe-L-Gln tripeptide containing an N-terminal amide moiety and a C-terminal ethyl propenoate Michael acceptor. Examination of approximately 500 compounds with varying N-terminal amides utilizing solid-phase synthesis and high-throughput assay techniques is described along with the solution phase preparation of several highly active molecules. A tripeptide Michael acceptor containing an N-terminal amide derived from 5-methylisoxazole-3-carboxylic acid is shown to exhibit potent, irreversible anti-3CP activity (k(obs)/[I] = 260,000 M(-1) s(-1); type-14 3CP) and broad-spectrum antirhinoviral properties (average EC50 = 0.47 microM against four different HRV serotypes).
本文描述了一系列不可逆人鼻病毒(HRV)3C蛋白酶(3CP)抑制剂的优化过程。这些抑制剂由一个含有N端酰胺部分和C端丙烯酸乙酯迈克尔受体的L-亮氨酸-L-苯丙氨酸-L-谷氨酰胺三肽组成。文中介绍了利用固相合成和高通量检测技术对约500种具有不同N端酰胺的化合物进行的研究,以及几种高活性分子的溶液相制备。一种含有源自5-甲基异恶唑-3-羧酸的N端酰胺的三肽迈克尔受体显示出强效、不可逆的抗3CP活性(k(obs)/[I] = 260,000 M(-1) s(-1);14型3CP)和广谱抗鼻病毒特性(对四种不同HRV血清型的平均EC50 = 0.47 microM)。